Emil D. Kakkis - Feb 7, 2024 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Feb 7, 2024
Transactions value $
-$1,350,000
Form type
4
Date filed
2/8/2024, 03:49 PM
Previous filing
Jan 2, 2024
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale -$1.35M -30K -5.27% $45.00 540K Feb 7, 2024 Direct F1, F2, F3
holding RARE Common Stock 2.26M Feb 7, 2024 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.69 to $45.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.